Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 1;20(13):e826-e830.
doi: 10.4244/EIJ-D-23-01073.

Paclitaxel-coated balloons for vulnerable lipid-rich plaques

Anna van Veelen  1 , I Tarik Küçük  1 , Hector M Garcia-Garcia  2 , Federico H Fuentes  2 , Yirga Kahsay  2 , Ronak Delewi  1 , Marcel A M Beijk  1 , Alexander W den Hartog  1 , Maik J Grundeken  1 , M Marije Vis  1 , José P S Henriques  1 , Bimmer E P M Claessen  1
Affiliations

Paclitaxel-coated balloons for vulnerable lipid-rich plaques

Anna van Veelen et al. EuroIntervention. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

R. Delewi has received educational grants from Edwards Lifesciences and Boston Scientific, outside the submitted work. H.M. Garcia-Garcia has received research grants from Philips, Abbott, Boston Scientific, Corflow, Neovasc, MedAlliance, Medis, and Biotronik; speaker fees from ACIST, Medis, and Boston Scientific; and honoraria for participation in the Abbott Advisory Board. J.P.S. Henriques has received research grants from Health~Holland, B. Braun, and Infraredx/Nipro to conduct the current study; and research grants from ZonMw, AstraZeneca, and Abbott, outside the submitted work. B.E.P.M Claessen has received speaker fees from Abiomed; and consultancy fees from Amgen, Sanofi, Boston Scientific, and Philips, outside the submitted work. The other authors have no conflicts of interest to declare.

Figures

Central illustration
Central illustration. DEBuT-LRP study.
Schematic overview of the DEBuT-LRP study with the primary outcome of change in maxLCBI4mm from baseline to 9-month follow-up in paclitaxel-treated lipid-rich plaques. In the DEBuT-LRP study, patients presenting with non-ST-segment elevation acute coronary syndromes underwent intravascular ultrasound combined with near-infrared spectroscopy (IVUS-NIRS). Lesions with a maxLCBI4mm ≥325 underwent additional paclitaxel-coated balloon treatment. Patients underwent repeat IVUS-NIRS after 9-month follow-up, and the maxLCBI4mm was significantly reduced compared with baseline. Red dots indicate the baseline measurement of maxLCBI4mm of the individual patients, and blue dots indicate the 9-month measurement. On both sides of the graph the median with interquartile range is displayed as horizontal lines. maxLCBI4mm: maximum lipid-core burden index in a 4 mm segment
See this image and copyright information in PMC

References

    1. Steen DL, Khan I, Andrade K, Koumas A, Giugliano RP. Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States. J Am Heart Assoc. 2022;11:e022198. - PMC - PubMed
    1. Erlinge D, Maehara A, Ben-Yehuda O, Bøtker HE, Maeng M, Kjøller-Hansen L, Engstrøm T, Matsumura M, Crowley A, Dressler O, Mintz GS, Fröbert O, Persson J, Wiseth R, Larsen AI, Okkels Jensen, Nordrehaug JE, Bleie Ø, Omerovic E, Held C, James SK, Ali ZA, Muller JE, Stone GW PROSPECT II Investigators. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet. 2021;397:985–95. - PubMed
    1. Chowdhury MM, Singh K, Albaghdadi MS, Khraishah H, Mauskapf A, Kessinger CW, Osborn EA, Kellnberger S, Piao Z, Lino Cardenas, Grau MS, Jaff MR, Rosenfield K, Libby P, Edelman ER, Lindsay ME, Tearney GJ, Jaffer FA. Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits. JACC Basic Transl Sci. 2020;5:685–95. - PMC - PubMed
    1. van Veelen, Küçük IT, Fuentes FH, Kahsay Y, Garcia-Garcia HM, Delewi R, Beijk MAM, den Hartog, Grundeken MJ, Vis MM, Henriques JPS, Claessen BEPM. First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study. J Clin Med. 2023;12:5807. - PMC - PubMed
    1. Stone GW, Maehara A, Lansky AJ, de Bruyne, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35. - PubMed

MeSH terms